Nebenwirkungen · Beyfortus
Beyfortus 50 mg solution for injection in pre-filled syringe Beyfortus 100 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 5
HOS-146163 · Präparat HOS-099456
MedDRA SOC MedDRA Preferred Term Frequency a Immune system disorders Hypersensitivity Not known b Skin and subcutaneous tissue disorders Rash Uncommon General disorders and administration Injection site reactionc Uncommon site conditions Pyrexia Uncommon a Adverse reaction from spontaneous reporting. b Rash was defined by the following grouped preferred terms: rash, rash maculo-papular, rash macular. c Injection site reaction was defined by the following grouped preferred terms: injection site reaction, injection site pain, injection site induration, injection site oedema, injection site swelling.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-01T17:30:00Z · SHA-256 6ddd9e8a4f288c6c9e290304a19baeffd2d4b6b593c6f38acd1d61a1b2295e11 · Passage 430d450a4be7f862f2ba8837ec1dc646ffe658e606aac4e1194a7d53288c4a9a · Zeichen 1078–2047 im Abschnitt